People · Operator
Named in public records as an officer, director or promoter · active 2020–2025 · Other Health Care, Biotechnology, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Wugen, Inc. | — | Other Health Care | Series D+ | $245.2M | $870.8M | 2025 |
| Spruce Biosciences, Inc. | — | Biotechnology | Series C | $191.6M | $274.5M | 2020 |
| Reneo Pharmaceuticals, Inc. | — | Pharmaceuticals | Series C | $159.4M | $519.8M | 2020 |
Bali Muralidhar at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Bali Muralidhar on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Niall O'Donnell | 3 | 7 |
| Michael Grey | 2 | 10 |
| Ed Mathers | 1 | 11 |
| Tiba Aynechi | 1 | 9 |
| Drew Dennison | 1 | 7 |
| Bosun Hau | 1 | 6 |
| Matthew Cooper | 1 | 5 |
| Peter Kiener | 1 | 4 |
| Kevin Li | 1 | 4 |
| Scott Weiner | 1 | 4 |
| Kenneth Harrison | 1 | 4 |
| Art Pappas | 1 | 3 |
| Edward T. Mathers | 1 | 3 |
| Richard King | 1 | 3 |
| Keith Vendola | 1 | 2 |
| Kumar Srinivasan | 1 | 2 |
| Daniel Spiegelman | 1 | 2 |
| JONAS HANSSON | 1 | 2 |
| Michael G. Grey | 1 | 2 |
| John P McKearn | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.